6876 logo

LAUNXP Biomedical TPEX:6876 Stock Report

Last Price

NT$25.60

Market Cap

NT$824.0m

7D

-1.5%

1Y

n/a

Updated

05 May, 2024

Data

Company Financials

LAUNXP Biomedical Co., Ltd

TPEX:6876 Stock Report

Market Cap: NT$824.0m

6876 Stock Overview

LAUNXP Biomedical Co., Ltd engages in the research and development of drugs for cancer patients.

6876 fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health0/6
Dividends0/6

LAUNXP Biomedical Co., Ltd Competitors

Price History & Performance

Summary of all time highs, changes and price drops for LAUNXP Biomedical
Historical stock prices
Current Share PriceNT$25.60
52 Week HighNT$30.35
52 Week LowNT$20.55
Beta0
1 Month Change-2.29%
3 Month Change-14.67%
1 Year Changen/a
3 Year Changen/a
5 Year Changen/a
Change since IPO14.29%

Recent News & Updates

Recent updates

Shareholder Returns

6876TW PharmaceuticalsTW Market
7D-1.5%-0.3%1.1%
1Yn/a2.2%28.2%

Return vs Industry: Insufficient data to determine how 6876 performed against the TW Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how 6876 performed against the TW Market.

Price Volatility

Is 6876's price volatile compared to industry and market?
6876 volatility
6876 Average Weekly Movement6.9%
Pharmaceuticals Industry Average Movement3.9%
Market Average Movement4.9%
10% most volatile stocks in TW Market8.8%
10% least volatile stocks in TW Market2.3%

Stable Share Price: 6876 has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine 6876's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
2015n/an/awww.launxp.com

LAUNXP Biomedical Co., Ltd engages in the research and development of drugs for cancer patients. It develops various drugs, which are in preclinical stage, including LXP5948 for non-small cell lung cancer and Alzheimer's disease; LXP5268 for triple negative breast cancer; LXP5101 for pancreatic cancer; LXP1788 for gastrointestinal cancer; and Virus-like particles for cancer and genetic defect treatment. The company was founded in 2015 and is based in Taichung, Taiwan.

LAUNXP Biomedical Co., Ltd Fundamentals Summary

How do LAUNXP Biomedical's earnings and revenue compare to its market cap?
6876 fundamental statistics
Market capNT$824.03m
Earnings (TTM)NT$0
Revenue (TTM)n/a

n/a

P/E Ratio

n/a

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
6876 income statement (TTM)
RevenueNT$0
Cost of RevenueNT$0
Gross ProfitNT$0
Other ExpensesNT$0
EarningsNT$0

Last Reported Earnings

n/a

Next Earnings Date

n/a

Earnings per share (EPS)0
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0.0%

How did 6876 perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.